Imperial College London


Faculty of MedicineDepartment of Infectious Disease

Chair in Mucosal Infection and Immunity



+44 (0)20 7594 5206r.shattock




453Wright Fleming WingSt Mary's Campus






BibTex format

author = {Badamchi-Zadeh, A and McKay, PF and Korber, BT and Barinaga, G and Walters, AA and Nunes, A and Gomes, JP and Follman, F and Tregoning, JS and Shattock, RJ},
doi = {10.3389/fimmu.2016.00162},
journal = {Frontiers in Immunology},
title = {A multi-component prime-boost vaccination regimen with a consensus MOMP antigen enhances Chlamydia trachomatis clearance},
url = {},
volume = {7},
year = {2016}

RIS format (EndNote, RefMan)

AB - Background: A vaccine for Chlamydia trachomatis is of urgent medical need. We explored bioinformatic approaches to generate an immunogen against C. trachomatis that would induce cross-serovar T cell responses as (i) CD4+ T cells have been shown in animal models and human studies to be important in chlamydial protection, and (ii) antibody responses may be restrictive and serovar-specific.Methods: A consensus antigen based on over 1,500 MOMP sequences provided high epitope coverage against the most prevalent C. trachomatis strains in silico. Having designed the T cell immunogen, we assessed it for immunogenicity in prime-boost regimens. This consensus MOMP transgene was delivered using plasmid DNA, Human Adenovirus-5 (HuAd5) or modified vaccinia Ankara (MVA) vectors with or without MF59® adjuvanted recombinant MOMP protein. Results: Different regimens induced distinct immune profiles. The DNA-HuAd5-MVA-Protein (DAMP) vaccine regimen induced a cellular response with a Th1 biased serum antibody response, alongside high serum and vaginal MOMP-specific antibodies. This regimen significantly enhanced clearance against intravaginal C. trachomatis serovar D infection in both BALB/c and B6C3F1 mouse strains. This enhanced clearance was shown to be CD4+ T cell dependent. Future studies will need to confirm the specificity and precise mechanisms of protection. Conclusions: A C. trachomatis vaccine needs to induce a robust cellular response with broad cross-serovar coverage and that a heterologous prime-boost regimen may be an approach to achieve this.
AU - Badamchi-Zadeh,A
AU - McKay,PF
AU - Korber,BT
AU - Barinaga,G
AU - Walters,AA
AU - Nunes,A
AU - Gomes,JP
AU - Follman,F
AU - Tregoning,JS
AU - Shattock,RJ
DO - 10.3389/fimmu.2016.00162
PY - 2016///
SN - 1664-3224
TI - A multi-component prime-boost vaccination regimen with a consensus MOMP antigen enhances Chlamydia trachomatis clearance
T2 - Frontiers in Immunology
UR -
UR -
VL - 7
ER -